Wasn’t expecting much from this base CORE-NK therapy because i believe this is just an allogeneic NK cell - not enhanced, just a plain NK cell (someone correct me if I’m wrong). One complete response on a heavily pre-treated Phase 1 subject, that’s not bad to me.
Also, I don’t think they’ve triggered the licensing option so I think they were waiting for these results before making a decision.
I think we’re going sideways/lower in 2022 though because of inflation, Russia-Ukraine, and risk-off market behaviour. Seems like a 2023 play though will all their assets coming to play around that time.
Ann: CORE NK Platform Phase 1 Clinical Data Presentation, page-11
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $11.72K | 2.783M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2757364 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 15260220 | 25 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |